Fund of the Week: Fidelity Select Biotechnology (FBIOX)

Welcome to MutualFunds.com

Please help us personalize your experience and select the one that best describes you.

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission

We hope you enjoy your experience

Channels

Fixed income news, reports, video and more.

Municipal bonds news, reports, video and more.

Practice management news, reports, video and more.

Portfolio management news, reports, video and more.

Retirement news, reports, video and more.

Learn from industry thought leaders and expert market participants.

Deepen your understanding of Responsible Investing and learn how it can potentially help you build a more successful practice.

Advisors

Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.

Content focused on helping financial advisors build successful client relationships and grow their business.

Content geared towards helping financial advisors build better client portfolios.

Get insights on the industry trends and investment news from leading fund managers and experts.

Fund of the Week: Fidelity Select Biotechnology (FBIOX)

Fidelity Investments logo
There have been a few industries that have been outperforming the S&P 500 since the beginning of 2015 – one of them being the biotechnology industry. While this run is nothing new, it is notable to mention that this industry is off to a good start for the year. This week, we have chosen the Fidelity® Select Biotechnology Fund (Liquid error: internal) as our fund of the week.

Inside the Fund

The fund was launched in 1985 and is managed by Rajiv Kaul. Currently, it has about $12 billion in assets under management (AUM). This fund is composed of healthcare companies of all sizes. The majority of these companies are based in the United States.

So far in 2015, the fund is up about 11%, which is in-line with the iShares NASDAQ Biotechnology Index (IBB) and well above the S&P 500 index, which is up about 3%.

Historical Performance

Largest Holdings

Nearly 30% of the fund’s portfolio is comprised of its top 5 holdings.

The Bottom Line

The biotechnology industry is an industry that many aggressive investors have kept a close eye on over the years. Investors seeking exposure to the industry may consider a mutual fund like the Fidelity® Select Biotechnology (Liquid error: internal).

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Popular Articles

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.


Read Next

Fidelity Investments logo

Fund of the Week: Fidelity Select Biotechnology (FBIOX)

There have been a few industries that have been outperforming the S&P 500 since the beginning of 2015 – one of them being the biotechnology industry. While this run is nothing new, it is notable to mention that this industry is off to a good start for the year. This week, we have chosen the Fidelity® Select Biotechnology Fund (Liquid error: internal) as our fund of the week.

Inside the Fund

The fund was launched in 1985 and is managed by Rajiv Kaul. Currently, it has about $12 billion in assets under management (AUM). This fund is composed of healthcare companies of all sizes. The majority of these companies are based in the United States.

So far in 2015, the fund is up about 11%, which is in-line with the iShares NASDAQ Biotechnology Index (IBB) and well above the S&P 500 index, which is up about 3%.

Historical Performance

Largest Holdings

Nearly 30% of the fund’s portfolio is comprised of its top 5 holdings.

The Bottom Line

The biotechnology industry is an industry that many aggressive investors have kept a close eye on over the years. Investors seeking exposure to the industry may consider a mutual fund like the Fidelity® Select Biotechnology (Liquid error: internal).

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Popular Articles

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.


Read Next